Valor de la 18 F-FDG-PET/CT en la estadificación inicial de pacientes con cáncer de tiroides de moderado/alto riesgo con subtipos histológicos agresivos.
Value of the 18 F-FDG-PET/CT in the initial staging of patients with high-risk thyroid cancer with aggressive histological subtypes.
Keywords:
aggressive thyroid cancer, 131 I, glucose transporters, thyroglobulin, TgAb
Abstract
In recent years, positron emission tomography / computed tomography (18F-FDG-PET / CT) or 2-(18F) - fluoro-2-deoxy-D-glucose has becomean essential tool for the postoperative treatment of patients with differentiated thyroid cancer (CDT), and it is widely used in selected clinical situations. The most valuable role that 18 F-FDG -PET / CT plays in clinical practice is that it can be used to obtain prognostic information in patients with increasing levels of thyroglobulin (Tg) and negative radioactive iodine (131I) body scan and ablation with 131I. The 18 F-FDG -PET / CT may also have a potential role in the initial staging and monitoring of high-risk patients with aggressive histological sub-types, identifying patients with a higher risk of disease-specific mortality, and managing patients with disease refractory to 131 I. Several articles support the hypothesis that the uptake of 18 F-FDG may have prognostic value in CDT. On the one hand, the uptake of 18 F-FDG in primary thyroid cancer is related to the expression and differentiation of the glucose transporter (GLUT). On the other hand, an association has been found between the uptake of 18 F- FDG and the aggressive histological characteristics, tumor size, and lymph node metastases.
Downloads
Download data is not yet available.
References
Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I131 whole-body scan, by restaging 18F-FDG PET/CT. Hell J Nucl Med 2016 ;19(3):208-217.
Liu M, Cheng L, Jin Y, Ruan M, Sheng S, Chen L. Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep 2018; 8(1): 4352. doi: 10.1038/s41598-018-22656-4.
Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139(5 Pt 1):346-351.
Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Toteda M, Redler A, Ronga G, Filetti S, Monzani F; PTC Study Group. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid 2014;24(7):1139-1145.
Morbelli S, Ferrarazzo G, Pomposelli E, Pupo F, Pesce G, Calamia I, Fiz F, Clapasson A, Bauckneht M, Minuto M, Sambuceti G, Giusti M, Bagnasco M. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications. J Endocrinol Invest 2017;40(4):417-424.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1-133. doi: 10.1089/ thy.2015.0020.
Pacini F, Fuhrer D, Elisei R ,Handkiewicz-Junak D, Leboulleux S, Luster M, Schlumberger M, Smit JW. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J 2022; 11 (1): e210046. doi: 10.1530/ETJ-21-0046.
Wong KS, Barletta JA. The new endocrine WHO classification: What does this mean for thyroid cytology? Cancer Cytopathol 2022;130: 658-662. https://doi.org/10. 1002/cncy.22634
Triviño Ibáñez EM. Utilidad de la 18F-FDG PET/CT precoz en el manejo terapéutico y estratificación dinámica del riesgo de pacientes con carcinoma diferenciado de tiroides de riesgo alto/intermedio. Facultad de Medicina Departamento de Medicina. Granada, 2015. Tesis Doctoral.
Colmenter L, Bastianello M, Estrada E. Conceptualizando VII: Papel de la glucosa y la 18F-FDG en tumores malignos, con enfoque en cáncer de tiroides (Parte I). Alasbimn Journal, 30 de julio, 2012.
Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W. 18FDG-Ganzkörper-PET bei differenzierten Schilddrüsenkarzinomen. Flipflop im Speichermuster von 18FDG und 131J [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and I]. Nuklearmedizin 1995;34(4):127-134.
Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I. ¹8F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012;39(9):1373-1380.
Iwano S, Kato K, Ito S, Tsuchiya K, Naganawa S. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer. Ann Nucl Med 2012;26(3):207-213.
Liu Y. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody. Nucl Med Commun 2016;37(6):577- 582.
Ruan M, Liu M, Dong Q, Chen L. Iodide and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. J Clin Endocrinol Metab 2015;100(5):1771-1779.
Nascimento C, Borget I, Ghuzlan AA, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey CH, Mirghani H, Baudin E, Schlumberger M, Leboulleux S. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 2015; 25 (4):437-444. doi:10.1089/thy.2014.0320 10.1089/ thy.2014.0320.
Riemann B, Uhrhan K, Dietlein M, Schmidt D, Kuwert T, Dorn R, Sciuk J, Kodalle T, Schober O. Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study. Nuklearmedizin. 2013;52(1):1-6.
Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47(8):1260-1266.
Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ. 18F- FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008;18(7):713-719.
Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2020;47(1):61-77. doi: 10.1007/ s00259-019-04458-6. Epub 2019 Sep 4.
Oh JM, Ahn BC. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. The ranostics 2021;11(13):6251-6277. doi: 10.7150/thno.
Piccardo A, Puntoni M, Bertagna F, Treglia G, Foppiani L, Arecco F, Giubbini R, Naseri M, Cistaro A, Cabria M, Bardesono F, Ceriani L, Orlandi F, Giovanella L. ¹8F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging 2014;41(8):1482-1491.
Stangierski A, Woliński K, Czepczyński R, Czarnywojtek A, Lodyga M, Wyszomirska A, Janicka-Jedyńska M, Bączyk M, Ruchała M. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination. PLoS One 2014;9(10):e109612. doi: 10.1371/journal.pone.0109612.
Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, Lumbroso J, Travagli JP, Hartl D, Baudin E, Schlumberger M, Leboulleux S. Is 18F- fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid no dules with indeterminate fine needle aspiration cytology? Thyroid 2012;22(2):165- 172. doi: 10.1089/thy.2011.0255. Epub 2012 Jan 18.
Liu Y. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody. Nucl Med Commun 2016;37(6):577-582.
Kim TH, Ji YB, Song CM, Kim JY, Choi YY, Park JS, Tae K. SUVmax of 18F-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume. World J Surg Oncol 2015;13:217.
Leboulleux S, Borget I, Schlumberger M. Postoperative radioactive iodine administration in patients with low-risk thyroid cancer. Nat Rev Endocrinol 2022;18(10):585- 586. doi: 10.1038/s41574-022-00709-z.
Liu M, Cheng L, Jin Y, Ruan M, Sheng S, Chen L. Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep 2018; 8(1): 4352. doi: 10.1038/s41598-018-22656-4.
Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139(5 Pt 1):346-351.
Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Toteda M, Redler A, Ronga G, Filetti S, Monzani F; PTC Study Group. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid 2014;24(7):1139-1145.
Morbelli S, Ferrarazzo G, Pomposelli E, Pupo F, Pesce G, Calamia I, Fiz F, Clapasson A, Bauckneht M, Minuto M, Sambuceti G, Giusti M, Bagnasco M. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications. J Endocrinol Invest 2017;40(4):417-424.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1-133. doi: 10.1089/ thy.2015.0020.
Pacini F, Fuhrer D, Elisei R ,Handkiewicz-Junak D, Leboulleux S, Luster M, Schlumberger M, Smit JW. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J 2022; 11 (1): e210046. doi: 10.1530/ETJ-21-0046.
Wong KS, Barletta JA. The new endocrine WHO classification: What does this mean for thyroid cytology? Cancer Cytopathol 2022;130: 658-662. https://doi.org/10. 1002/cncy.22634
Triviño Ibáñez EM. Utilidad de la 18F-FDG PET/CT precoz en el manejo terapéutico y estratificación dinámica del riesgo de pacientes con carcinoma diferenciado de tiroides de riesgo alto/intermedio. Facultad de Medicina Departamento de Medicina. Granada, 2015. Tesis Doctoral.
Colmenter L, Bastianello M, Estrada E. Conceptualizando VII: Papel de la glucosa y la 18F-FDG en tumores malignos, con enfoque en cáncer de tiroides (Parte I). Alasbimn Journal, 30 de julio, 2012.
Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W. 18FDG-Ganzkörper-PET bei differenzierten Schilddrüsenkarzinomen. Flipflop im Speichermuster von 18FDG und 131J [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and I]. Nuklearmedizin 1995;34(4):127-134.
Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I. ¹8F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012;39(9):1373-1380.
Iwano S, Kato K, Ito S, Tsuchiya K, Naganawa S. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer. Ann Nucl Med 2012;26(3):207-213.
Liu Y. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody. Nucl Med Commun 2016;37(6):577- 582.
Ruan M, Liu M, Dong Q, Chen L. Iodide and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. J Clin Endocrinol Metab 2015;100(5):1771-1779.
Nascimento C, Borget I, Ghuzlan AA, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey CH, Mirghani H, Baudin E, Schlumberger M, Leboulleux S. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 2015; 25 (4):437-444. doi:10.1089/thy.2014.0320 10.1089/ thy.2014.0320.
Riemann B, Uhrhan K, Dietlein M, Schmidt D, Kuwert T, Dorn R, Sciuk J, Kodalle T, Schober O. Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study. Nuklearmedizin. 2013;52(1):1-6.
Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47(8):1260-1266.
Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ. 18F- FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008;18(7):713-719.
Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2020;47(1):61-77. doi: 10.1007/ s00259-019-04458-6. Epub 2019 Sep 4.
Oh JM, Ahn BC. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. The ranostics 2021;11(13):6251-6277. doi: 10.7150/thno.
Piccardo A, Puntoni M, Bertagna F, Treglia G, Foppiani L, Arecco F, Giubbini R, Naseri M, Cistaro A, Cabria M, Bardesono F, Ceriani L, Orlandi F, Giovanella L. ¹8F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging 2014;41(8):1482-1491.
Stangierski A, Woliński K, Czepczyński R, Czarnywojtek A, Lodyga M, Wyszomirska A, Janicka-Jedyńska M, Bączyk M, Ruchała M. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination. PLoS One 2014;9(10):e109612. doi: 10.1371/journal.pone.0109612.
Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, Lumbroso J, Travagli JP, Hartl D, Baudin E, Schlumberger M, Leboulleux S. Is 18F- fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid no dules with indeterminate fine needle aspiration cytology? Thyroid 2012;22(2):165- 172. doi: 10.1089/thy.2011.0255. Epub 2012 Jan 18.
Liu Y. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody. Nucl Med Commun 2016;37(6):577-582.
Kim TH, Ji YB, Song CM, Kim JY, Choi YY, Park JS, Tae K. SUVmax of 18F-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume. World J Surg Oncol 2015;13:217.
Leboulleux S, Borget I, Schlumberger M. Postoperative radioactive iodine administration in patients with low-risk thyroid cancer. Nat Rev Endocrinol 2022;18(10):585- 586. doi: 10.1038/s41574-022-00709-z.
Published
2024-05-21
How to Cite
Colmenter, L. F., Daryanani, S., Zúñiga, S., & Vilar, J. (2024). Valor de la 18 F-FDG-PET/CT en la estadificación inicial de pacientes con cáncer de tiroides de moderado/alto riesgo con subtipos histológicos agresivos.: Value of the 18 F-FDG-PET/CT in the initial staging of patients with high-risk thyroid cancer with aggressive histological subtypes. Investigación Clínica, 65(2), 253-263. https://doi.org/10.54817/IC.v65n2a10
Section
Revisiones
